Research & Publications
Our research program is still burgeoning and primarily focuses on metabolic diseases, with particular emphasis on type 1 diabetes (T1D) and atherosclerotic cardiovascular disease (ASCVD). The etiopathogenesis of T1D is characterized by a detrimental cross-talk between the hematopoietic system and insulin-producing beta cells. There is also evidence that T1D is intrinsically linked with ASCVD above and beyond traditional cardiovascular risk factors. In that vein, our research ideology is that T1D is a cluster of metabolic abnormalities that involves not only the immune system and beta cells, but also the cardiovascular system, and we think that a definitive prevention or cure for T1D may require elimination of both insulin dependence and cardiovascular disease risk, at least, in some patients. We employ a combination of human statistical genetics and genomics, cellular and molecular/biochemical assays, and animal models to understand the pathological mechanisms in the hematopoietic system, beta cells, and the cardiovascular system, and how these are connected in T1D. Our exit plan is to identify and validate disease biomarkers for prediction, precision medicine, and preclinical translation that would facilitate transition to the bedside.
Autoimmune Diseases; Cardiovascular Diseases; Diabetes Mellitus, Type 1; DNA Transposable Elements; Genetics; Hematopoiesis; Hematopoietic Stem Cells; Islets of Langerhans; Myocardial Infarction; Genomics; Atherosclerosis; Epigenomics; Single-Cell Analysis; Clonal Hematopoiesis